newsfilter
← Latest News
PR Newswire·

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol - ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK, July 26, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (